|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
657803770[A20451931]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2006.05.01)(ÇöÀç¾à°¡)
\10 ¿ø/1Á¤(2002.07.27)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ÁÖȲ»öÀÇ ´çÀÇÁ¤
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100,1000TABS |
| ´ëÇ¥ÄÚµå |
8806578037705 |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
- µÎµå·¯±â¿¡ ÀÇÇÑ ¼Ò¾çÁõ Ä¡·á
- ½Å°æ¼ºÇǺο°, ¾Ë·¹¸£±â¼ºÇǺο°, Á¢Ã˼ºÇǺο°, ¾ÆÅäÇǼº ÇǺο°, Ç×¹® ¹× ¿ÜÀ½ºÎ ¼Ò¾çÁõ ÀÇ ¿ÏÈ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:244401ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
- ¼ºÀÎ : Æ®¸®¸ÞÇÁ¶óÁøÀ¸·Î¼ 1ȸ 2.5mg 1ÀÏ 4ȸ °æ±¸Åõ¿©ÇÑ´Ù.
- 3¼¼ ÀÌ»ó ¼Ò¾Æ : ÀÌ ¾àÀ¸·Î¼ 1ȸ 2.5mg Ãëħ½Ã 1ȸ ¶Ç´Â Çʿ信 µû¶ó 1ÀÏ 3ȸ Åõ¿©ÇÑ´Ù.
- 6°³¿ù-3¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ : ÀÌ ¾àÀ¸·Î¼ 1ȸ 1.25mg Ãëħ½Ã 1ȸ ¶Ç´Â Çʿ信 µû¶ó 1ÀÏ 3ȸ Åõ¿©ÇÑ´Ù.
¿¬·É,Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
- Æä³ëÄ¡¾ÆÁø°è ¾à¹° ¹× ±× À¯»çÈÇÕ¹°¿¡ °ú¹ÎÁõ ȯÀÚ
- È¥¼ö»óÅ ȯÀÚ ¶Ç´Â ¹Ù¸£ºñÅ»°è ¾à¹°, ¸¶ÃëÁ¦ µîÀÇ ÁßÃ߽Űæ¾ïÁ¦Á¦¸¦ ´ë·®À¸·Î Åõ¿©ÁßÀΠȯÀÚ
- °ñ¼ö¾ïÁ¦ ȯÀÚ
- ½Å»ý¾Æ ¹× ¹Ì¼÷¾Æ
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ, ¼öÀ¯ºÎ
- ÁßÁõ Áúȯ ¶Ç´Â Å»¼ö»óÅÂÀÇ ¼Ò¾Æ
- ³ì³»Àå ȯÀÚ
- Àü¸³¼±ºñ´ë µî ÇϺΠ¿ä·Î Æó»ö¼º Áúȯ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ¼Ò¾Æ ¹× °í·ÉÀÚ
- õ½Ä¹ßÀÛ ¶Ç´Â ±Þ¸¸¼º È£Èí±â Àå¾Ö ȯÀÚ(ƯÈ÷ ¼Ò¾Æ¿¡¼ ±âħ ¹Ý»ç¸¦ ¾ïÁ¦ÇÑ´Ù.)
- ÇùÂø¼º ¼Òȼº ±Ë¾ç ¹× À¯¹®½ÊÀÌÁöÀå Æó»ö ȯÀÚ
- °£±â´É Àå¾Ö ȯÀÚ
- MAO ÀúÇØÁ¦¸¦ Åõ¿©ÁßÀΠȯÀÚ
- ±Þ¸¸¼º È£Èí±â Àå¾Ö ȯÀÚ
- ½ÉÇ÷°ü°è Áúȯ ȯÀÚ, ±Ë¾ç ÁúȯÀÇ º´·ÂÀÌ Àִ ȯÀÚ
- ¼ö¸é¹«È£ÈíÁõÀÇ º´·Â ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- °ú¹ÎÁõ :
µÎµå·¯±â, ÇǺο°, õ½Ä, ÈĵκÎÁ¾, ¸Æ°ü½Å°æ¼º ºÎÁ¾, ±¤¼±°ú¹ÎÁõ, ·çǪ½ºÈ«¹Ý¼ºÁõÈıº, ¾Æ³ªÇʶô½Ã¾ç¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Ç÷¾×°è : ¹«°ú¸³±¸Áõ, ¹éÇ÷±¸°¨¼ÒÁõ, ¹üÇ÷±¸°¨¼ÒÁõ, ¿ëÇ÷¼ººóÇ÷, Ç÷Àå ÄÝ·¹½ºÅ×·ÑÄ¡ »ó½Â, Ç÷¼ÒÆÇ°¨¼Ò¼ºÀÚ¹ÝÁõ, ¸¸¼º Ȳ´Þ, È«¹Ý, ¸»Ãʼº ºÎÁ¾ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ¼ÒȺҷ®, ±¸¿ª, ±¸Åä, »óº¹ºÎºÒÄè°¨, ¼³»ç, º¯ºñ, ±¸°¥, ½Ä¿å ¹× üÁßÁõ°¡°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Á¤½Å½Å°æ°è : Á¹À½ÀÌ °¡Àå ÈçÇϸç, Ãßü¿Ü·Î ºÎÀÛ¿ë(¹Ý±Ã±äÀå, ±Ù±äÀå ÀÌ»óÁõ, Á¤ÁºҴÉÁõ, ¼öÀǿÀå¾Ö, ÆÄŲ½¼Áõ), ¾îÁö·¯¿ò, µÎÅë, ±Çۨ, À̸í, ÇùÁ¶ºÒ´É, ÇÇ·Î, ½Ã¾ß¸ù·Õ, ´ÙÇà°¨, º¹½Ã, ½Å°æºÒ¾È, ºÒ¸é, ÁøÀü ¹× ´ë¹ßÀÛ°æ·Ã, ÈïºÐ, ±äÀå»óÅÂ, ½Å°æ¿°°ú È÷½ºÅ׸®, ¾È±¸¿îµ¿¹ßÁõ, ¼ö¸é¹æÇØ/¾Ç¸ù, °¡¼ºÁ¤½ÅºÐ¿Áõ(pseudoschizoprenia)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
½ÉÇ÷°ü°è : ±â¸³¼º ÀúÇ÷¾Ð, ½É±Þ¸·Áõ, ¼¸Æ, ½Ç½Å, ½ÉÀåÁ¤Áö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ºñ´¢±â°è : ºó´¢, ¹è´¢°ï¶õ, ¿äÀú·ù, Á¶±â¿ù°æ, À¯ÁóºÐºñ, ³²¼ºÀÇ ¿©¼ºÇü À¯¹æ, ¼º¿å°¨Åð, »çÁ¤¾ïÁ¦, °¡(Ê£)ÀӽŹÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
È£Èí±â°è : ±â°üÁö ºÐºñ¹°ÀÇ ³óÈ, õ¸íÀ½ ¶Ç´Â °¡½¿ÀÇ ¾Ð¹Ú°¨, ÄÚ¸·ÈûÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£: ´Ù¸¥ Æä³ëÄ¡¾ÆÁø°è ÈÇÕ¹°À» Åõ¿©ÇÑ È¯ÀÚ¿¡¼ °£Àå¾Ö°¡ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
Àå±âÅõ¿©½Ã : ´Ù·®ÀÇ Æä³ëÄ¡¾ÆÁø°è ¾à¹°À» Àå±âÅõ¿©ÇÏ¸é ³ëÃâµÈ ºÎÀ§ÀÇ ÇǺο¡ »ö¼Ò Ä§ÂøÀÌ ÀϾÙ.
|
| ÀϹÝÀû ÁÖÀÇ |
Á¹À½À» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» Åõ¿©ÁßÀΠȯÀÚ´Â ÀÚµ¿Â÷ ¿îÀü µî À§ÇèÇÑ ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. |
| »óÈ£ÀÛ¿ë |
- ÁßÃ߽Űæ¾ïÁ¦Á¦(¾ÆÆí, ¸¶ÃëÁ¦, Ç×È÷½ºÅ¸¹ÎÁ¦, ¹Ù¸£ºñÅ»·ù), Ç÷¾Ð°ÇÏÁ¦ ¶Ç´Â ¾ÆÆ®·ÎÇɾç ÀÛ¿ë ¾à¹°°úÀÇ º´¿ë ¶Ç´Â ¾ËÄÚ¿Ã ¼·Ãë¿¡ ÀÇÇØ »óÈ£ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- MAO ÀúÇØÁ¦¿Í º´¿ë½Ã °íÇ÷¾Ð, Ãßü¿Ü·Î ¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
- ´ÙÀ½ ¾à¹°Àº Æä³ëÄ¡¾ÆÁø°è ¾à¹°ÀÇ ¹ÝÀÀÀ» Áõ°½ÃŲ´Ù. :
°æ±¸¿ë ÇÇÀÓ¾à, ÇÁ·Î°Ô½ºÅ×·Ð, ·¹¼¼¸£ÇÉ, ¿°»ê´Ò¸®µå¸°
|
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
- ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
- ÀÓ½ÅÁß Æä³ëÄ¡¾ÆÁø°è ¾à¹°À» Åõ¿©ÇÑ »ê¸ðÀÇ ¿µ¾Æ¿¡°Ô¼ Ȳ´Þ°ú Ãßü¿Ü·Î ÁõÈıºÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
|
| ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© |
- ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
- ¼Ò¾ÆÀÇ °æ¿ì ÈïºÐÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç °ú·®Åõ¿©·Î ȯ°¢, °æ·Ã, ±Þ»ç µîÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- ´Ù¸¥ Æä³ëÄ¡¾ÆÁø°è ¾à¹°À» ¼Ò¾Æ(ƯÈ÷ 2¼¼ÀÌÇÏ)¿¡ Åõ¿©ÇÑ °æ¿ì, À¯¾Æ µ¹¿¬»ç¸ÁÁõÈıº(SIDS) ¹× À¯¾Æ ¼ö¸é½Ã ¹«È£Èí ¹ßÀÛÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
- °í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿©
ÀúÇ÷¾Ð, ½Ç½Å, Áßµ¶¼º È¥¶õ, Ãßü¿Ü·Î ÁõÈıº, ƯÈ÷ ÆÄŲ½¼Áõ, °ú´ëÁøÀü µîÀÌ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| °ú·®Åõ¿© ¹× óġ |
- °ú·®Åõ¿©½Ã ³ªÅ¸³ª´Â Áõ»ó¿¡´Â ÀúÇ÷¾Ð, È£Èí°ï¶õ, ÀǽĺҸí, À§ÀåÀå¾Ö, ¾ÆÆ®·ÎÇɾçÀÛ¿ë(±¸°¥, µ¿°øÀÌ¿Ï ¹× °íÁ¤, È«Á¶ µî)ÀÌ ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Á¶¼ÓÈ÷ À§¼¼Ã´À» ÇØ¾ßÇϸç ÃÖÅäÁ¦ µî ±¸Å並 À¯¹ßÇϴ óġ´Â ÇÇÇÑ´Ù.
- °ú·®Åõ¿©½Ã óġ·Î´Â Ãßü¿Ü·ÎÁõ»ó¿¡´Â ÇׯÄŲ½¼¾à¹°, ¹Ù¸£ºñÅ»·ù, ¿°»êµðÆæÈ÷µå¶ó¹ÎÀ» Åõ¿©ÇÒ ¼ö ÀÖ´Ù. ´Ù¸¸, °æ·ÃÀ» ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î °¢¼ºÁ¦´Â ÇÇÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Trimeprazine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Trimeprazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
|
| Pharmacology |
Trimeprazine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Trimeprazine (also known as Alimemazine) is a tricyclic antihistamine, similar in structure to the phenothiazine antipsychotics, but differing in the ring-substitution and chain characteristics. Trimeprazine is in the same class of drugs as chlorpromazine (Thorazine) and trifluoperazine (Stelazine); however, unlike the other drugs in this class, trimeprazine is not used clinically as an anti-psychotic. It acts as an anti-histamine, a sedative, and an anti-emetic (anti-nausea). Trimeprazine is used principally as an anti-emetic, to prevent motion sickness or as an anti-histamine in combination with other medications in cough and cold preparations. Tricyclic antihistamines are also structurally-related to the tricyclic antidepressants, explaining the antihistaminergic adverse effects of these two drug classes and also the poor tolerability profile of tricyclic H1-antihistamines.
|
| Absorption |
Trimeprazine¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed in the digestive tract.
|
| Pharmacokinetics |
Trimeprazine TartrateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : Àß Èí¼öµÊ
- »ýü³» ÀÌ¿ë·ü : Á¤Á¦ (¾à 70%), ¼¹æÇü ݼ¿Á¦µµ ÀÌ¿Í À¯»ç
- ´ë»ç : °£´ë»ç, ´ëºÎºÐ n-desalkylü·Î ´ë»çµÊ
- ¹Ý°¨±â : Æò±Õ 4.78½Ã°£
- ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£
- ½Ã·´ : 3.5 ½Ã°£
- Á¤Á¦ : 4.5 ½Ã°£
|
| Biotransformation |
Trimeprazine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Trimeprazine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.
|
| Drug Interactions |
Trimeprazine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Trimeprazine¿¡ ´ëÇÑ Description Á¤º¸ A phenothiazine derivative that is used as an antipruritic. [PubChem]
|
| Dosage Form |
Trimeprazine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet Oral
|
| Drug Category |
Trimeprazine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AntipruriticsPhenothiazine Derivatives
|
| Smiles String Canonical |
Trimeprazine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12
|
| Smiles String Isomeric |
Trimeprazine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H](CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12
|
| InChI Identifier |
Trimeprazine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
|
| Chemical IUPAC Name |
Trimeprazine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|